Eric Lefkofsky is the co-founder of Groupon. He is a billionaire. He has built his fortune by saving money for his customers on travel as well as restaurants. This is done through Groupon. The latest startup from Eric Lefkofsky is Tempus. Through this venture, he is making an effort to save their lives and more information click here.
Tempus is based in Chicago. It makes use of genomic sequencing in order to help doctors in customizing their cancer treatments based on the condition and needs of their patients. Now Eric Lefkofsky has announced that it has managed to raise $70 million. This was through its series C funding round. It has received this funding from Revolution Growth along with New Enterprise Associates that are investors.
Eric Lefkofsky further claimed that this funding would become a part of the $130 million that has been raised since Tempus was started in 2015. Eric Lefkofsky had co-founded Tempus with Brad Keywell who has been his long-time business partner. With this latest fundraising, the valuation of Tempus is being termed at around $700 million and Eric on Facebook.
Eric Lefkofsky is the CEO of Tempus. He remains the largest individual investor. The new investors, namely, NEA and Revolution Growth, have been funding other companies too. These include the stock trading app Robinhood being funded by NEA, besides the salad chain Sweetgreen being funded by Revolution. The personal genomics firm 23andMe is being funded by NEA. It was Steve Case who had founded Revolution Growth. It is doing two to three investments each year in startups that are not based in Silicon Valley or New York City and Eric’s lacrosse camp.
Tempus makes use of technology in order to compile large amounts of genomic as well as clinical data. This is from cancer patients. Now doctors can use it for personalizing treatment and https://www.recode.net/2015/11/3/11620318/groupon-replaces-ceo-eric-lefkofsky-with-coo-rich-williams.
Eric Lefkofsky says that in oncology, there had been small datasets that were highly disorganized too. But technology has led to new possibilities opening out. In this way, huge amounts of molecular along with clinical data can be used to benefit patients.
Tempus has recently announced its partnership with the Mayo Clinic. This way the largest library of such data is being built to personalize cancer care and what Eric knows.